等待開盤 01-29 09:30:00 美东时间
-0.330
-3.20%
今日重点评级关注:Oppenheimer:维持Pelthos Therapeutics"跑赢大市"评级,目标价从57美元升至60美元;Small Cap Consumer Research:维持Lands' End"买入"评级,目标价从20美元升至45美元
01-27 10:02
9 analysts have shared their evaluations of Personalis (NASDAQ:PSNL) during the...
01-27 04:01
Guggenheim analyst Subbu Nambi maintains Personalis (NASDAQ:PSNL) with a Buy and raises the price target from $12 to $13.
01-27 00:38
Personalis CFO and COO Aaron Tachibana Reports Disposal of Common Shares Aaron Tachibana, Chief Financial Officer and Chief Operating Officer of Personalis Inc., reported a disposal of common shares of Personalis Inc. The full filing can be accessed through the link below. Disclaimer: This news brie
01-24 07:03
Cathie Wood’s ARK Invest (ARKK) deepened investment in AI chipmakers, gene-editing companies, and autonomous-driving developers while continuing to trim positions in Tesla (TSLA) and several mature te...
01-19 20:35
New NeXT Personal® extension empowers clinicians to identify emerging resistance and therapeutically targetable mutations during disease monitoring and surveillance
01-13 05:02
Cathie Wood’s ARK Invest repositions toward long-term innovation themes like advanced air mobility, autonomous transport, and gene editing during the last week, while reducing exposure to more matur...
01-12 20:30
今日重点评级关注:Needham:维持Cartesian Therapeutics"买入"评级,目标价从40美元升至42美元;Piper Sandler:维持Acrivon Therapeutics"超配"评级,目标价从6美元升至8美元
01-12 14:09
BTIG analyst Mark Massaro reiterates Personalis (NASDAQ:PSNL) with a Buy and maintains $12 price target.
01-09 18:26
Personalis shares are trading lower. The company reported Q4 and FY25 prelimina...
01-09 02:00